T Cell Immunoglobulin and Mucin Domain 3 (TIM-3) in Cutaneous Melanoma: A Narrative Review
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
T Cell Immunoglobulin and Mucin Domain 3 (TIM-3) in Cutaneous Melanoma: A Narrative Review
Authors
Keywords
-
Journal
Cancers
Volume 15, Issue 6, Pages 1697
Publisher
MDPI AG
Online
2023-03-10
DOI
10.3390/cancers15061697
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Melanoma antigens recognized by T cells and their use for immunotherapy
- (2023) Shigeki Ohta et al. EXPERIMENTAL DERMATOLOGY
- TIM-3 shuttled by MV3 cells-secreted exosomes inhibits CD4+ T cell immune function and induces macrophage M2 polarization to promote the growth and metastasis of melanoma cells
- (2022) Xinghui Li et al. Translational Oncology
- Inhibition of Melanoma Cell–Intrinsic Tim-3 Stimulates MAPK-Dependent Tumorigenesis
- (2022) Tobias Schatton et al. CANCER RESEARCH
- Melanoma classification and management in the era of molecular medicine
- (2022) Sarem Rashid et al. DERMATOLOGIC CLINICS
- Clinical Trials in Melanoma
- (2022) Cimarron E. Sharon et al. Surgical Oncology Clinics of North America
- Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
- (2022) Jordan W Conway et al. Journal for ImmunoTherapy of Cancer
- Biological drug and drug delivery-mediated immunotherapy
- (2021) Qingqing Xiao et al. Acta Pharmaceutica Sinica B
- HMGB1-TIM3-HO1: A New Pathway of Inflammation in Skin of SARS-CoV-2 Patients? A Retrospective Pilot Study
- (2021) Gerardo Cazzato et al. Biomolecules
- Lipopolysaccharide mediates time-dependent macrophage M1/M2 polarization through the Tim-3/Galectin-9 signalling pathway
- (2019) Wang Zhang et al. EXPERIMENTAL CELL RESEARCH
- Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion
- (2018) Lyndsay Avery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Human disease mutations highlight the inhibitory function of TIM-3
- (2018) Karen O. Dixon et al. NATURE GENETICS
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
- (2017) Wenwen Du et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- TIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis
- (2017) Yang Zhang et al. Oncotarget
- Primary malignant melanoma
- (2016) A. Ferhat Mısır et al. SAUDI MEDICAL JOURNAL
- Cutaneous Malignant Melanoma
- (2014) Ossama Abbas et al. AMERICAN JOURNAL OF DERMATOPATHOLOGY
- Orchestrating immune check-point blockade for cancer immunotherapy in combinations
- (2014) Jose Luis Perez-Gracia et al. CURRENT OPINION IN IMMUNOLOGY
- Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion
- (2014) Robert L. Ferris et al. JOURNAL OF IMMUNOLOGY
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
- (2014) I. P. da Silva et al. Cancer Immunology Research
- Tim-3 Expression Defines Regulatory T Cells in Human Tumors
- (2013) Jing Yan et al. PLoS One
- Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
- (2012) L. C. Ndhlovu et al. BLOOD
- Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas
- (2012) Muhammad Baghdadi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Taming dendritic cells with TIM-3: another immunosuppressive strategy used by tumors
- (2012) Jaina Patel et al. Immunotherapy
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines
- (2009) William D. Hastings et al. EUROPEAN JOURNAL OF IMMUNOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started